Critical appraisal of a quadrivalent CRM(197) conjugate vaccine against meningococcal serogroups A, C W-135 and Y (Menveo(®)) in the context of treatment and prevention of invasive disease

Worldwide, invasive meningococcal disease affects about 500,000 people annually. Case fatality in developed countries averages 10%, and higher rates are reported in less prosperous regions. According to the World Health Organization, the most important pathogenic serogroups are A, B, C, W-135, X, an...

Descripción completa

Detalles Bibliográficos
Autores principales: Bröker, Michael, Cooper, Brian, DeTora, Lisa M, Stoddard, Jeffrey J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2011
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3163984/
https://www.ncbi.nlm.nih.gov/pubmed/21904459
http://dx.doi.org/10.2147/IDR.S12716

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3163984/
https://www.ncbi.nlm.nih.gov/pubmed/21904459
http://dx.doi.org/10.2147/IDR.S12716

Ejemplares similares